Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other financing activities (2021 - 2025)

Guided Therapeutics (GTHP) has disclosed Other financing activities for 4 consecutive years, with -$32000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities changed N/A to -$32000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$33000.0 through Dec 2025, down 3200.0% year-over-year, with the annual reading at $30000.0 for FY2025, 3.45% up from the prior year.
  • Other financing activities hit -$32000.0 in Q4 2025 for Guided Therapeutics, down from -$31000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $722000.0 in Q3 2022 to a low of -$722000.0 in Q4 2022.
  • Historically, Other financing activities has averaged $4833.3 across 4 years, with a median of -$500.0 in 2024.
  • Biggest YoY gain for Other financing activities was 1064.52% in 2022; the steepest drop was 1064.52% in 2022.
  • Year by year, Other financing activities stood at $62000.0 in 2021, then plummeted by 1264.52% to -$722000.0 in 2022, then surged by 95.71% to -$31000.0 in 2024, then dropped by 3.23% to -$32000.0 in 2025.
  • Business Quant data shows Other financing activities for GTHP at -$32000.0 in Q4 2025, -$31000.0 in Q3 2024, and $30000.0 in Q2 2024.